Omega Launches Aerium With ‘Substantial’ Cash, Two Antibodies Against SARS-CoV-2
Former Takeda Vaccines President Is CEO
Its antibodies will enter the clinic soon, but pandemic- and epidemic-focused Aerium plans to raise series B funds to take the assets all the way to an EUA in the US and pursue antiviral drug development.
You may also be interested in...
Alnylam CEO Maraganore To Step Aside At End Of 2021
Founding CEO will remain involved with Alnylam’s scientific advisory board, while current president/COO Yvonne Greenstreet will move up to the chief executive’s office.
COVID-19 Vaccine Sponsors Want US FDA To Find Alternatives For Control-Arm Data After First EUA
US FDA must rethink guidance on maintaining placebo-control in COVID-19 trials after any vaccine gets an EUA, companies say, arguing current proposal may not be ethical or feasible. Disease organizations who agree with the hurdles to preserving placebo-control maintain this is a reason why any EUA must meet a very high standard.
Ionis Finds Its Footing Ahead Of Its First Big Commercial Step
Ionis will launch its first commercial product through a co-commercialization agreement with AstraZeneca early next year, in preparation for its first wholly-owned drug launches soon to follow.